On Tuesday, Adma Biologics Inc (NASDAQ: ADMA) was 3.01% up from the session before settling in for the closing price of $5.98. A 52-week range for ADMA has been $3.06 – $6.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 73.26%. When this article was written, the company’s average yearly earnings per share was at 326.92%. With a float of $219.51 million, this company’s outstanding shares have now reached $226.06 million.
The extent of productivity of a business whose workforce counts for 624 workers is very important to gauge.
Adma Biologics Inc (ADMA) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Adma Biologics Inc stocks. The insider ownership of Adma Biologics Inc is 3.82%, while institutional ownership is 74.31%. The most recent insider transaction that took place on Mar 19 ’24, was worth 2,503,920. In this transaction Director of this company sold 411,829 shares at a rate of $6.08, taking the stock ownership to the 2,115,671 shares. Before that another transaction happened on Mar 18 ’24, when Company’s Director sold 49,887 for $6.01, making the entire transaction worth $299,821. This insider now owns 2,527,500 shares in total.
Adma Biologics Inc (ADMA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 6.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 326.92% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
You can see what Adma Biologics Inc (ADMA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.44. Likewise, its price to free cash flow for the trailing twelve months is 348.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.13, a number that is poised to hit 0.06 in the next quarter and is forecasted to reach 0.50 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
The latest stats from [Adma Biologics Inc, ADMA] show that its last 5-days average volume of 1.82 million was inferior to 2.66 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 26.38%. Additionally, its Average True Range was 0.23.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 81.01%, which indicates a significant increase from 30.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.18% in the past 14 days, which was lower than the 40.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.87, while its 200-day Moving Average is $4.44. Now, the first resistance to watch is $6.30. This is followed by the second major resistance level at $6.44. The third major resistance level sits at $6.63. If the price goes on to break the first support level at $5.96, it is likely to go to the next support level at $5.77. The third support level lies at $5.63 if the price breaches the second support level.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
There are 228,220K outstanding shares of the company, which has a market capitalization of 1.41 billion. As of now, sales total 258,220 K while income totals -28,240 K. Its latest quarter income was 73,900 K while its last quarter net income were -17,640 K.
